Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

CRISPR01:59

CRISPR

49.8K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets.

bioRxiv : the preprint server for biology·2026
Same author

A multi-subunit autophagic capture complex facilitates degradation of ER-stalled MHC class I in pancreatic cancer.

Molecular cell·2026
Same author

Multivalent recognition of ferritin by full-length NCOA4 enables robust ferritinophagy.

Protein science : a publication of the Protein Society·2026
Same author

Rewriting endogenous human transcripts with dual CRISPR-guided 3' trans-splicing.

Cell systems·2026
Same author

Molecular Signatures of Pyomelanin Production in MDR <i>Acinetobacter baumannii</i>: A Proteomic Perspective.

Journal of proteome research·2026
Same author

Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

Journal for immunotherapy of cancer·2025

相关实验视频

Updated: Jun 13, 2025

Pooled CRISPR-Based Genetic Screens in Mammalian Cells
00:09

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Published on: September 4, 2019

21.8K

全基因组的CRISPR屏幕将PTGES3识别为一种新的AR调节器.

Haolong Li, James E Melnyk, Becky Xu Hua Fu

    bioRxiv : the preprint server for biology
    |June 12, 2025
    PubMed
    概括

    研究人员确定PTGES3是前列腺癌 (PCa) 中雄激素受体 (AR) 蛋白水平的关键调节者. 针对PTGES3提供了一个潜在的新策略,以克服对当前AR导向疗法的耐药性.

    更多相关视频

    Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
    07:37

    Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells

    Published on: January 31, 2025

    799
    High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
    09:44

    High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

    Published on: March 3, 2015

    9.5K

    相关实验视频

    Last Updated: Jun 13, 2025

    Pooled CRISPR-Based Genetic Screens in Mammalian Cells
    00:09

    Pooled CRISPR-Based Genetic Screens in Mammalian Cells

    Published on: September 4, 2019

    21.8K
    Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
    07:37

    Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells

    Published on: January 31, 2025

    799
    High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
    09:44

    High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

    Published on: March 3, 2015

    9.5K

    科学领域:

    • 在瘤学瘤学.
    • 分子生物学分子生物学
    • 遗传学 是一个遗传学.

    背景情况:

    • 雄激素受体 (AR) 是前列腺癌 (PCa) 的关键驱动因素.
    • 了解AR蛋白水平和活性的调节者对于开发新疗法至关重要.
    • 针对AR的现有疗法可能会导致耐药性.

    研究的目的:

    • 系统地识别调节AR蛋白水平和瘤性活性的基因.
    • 调查PTGES3作为PCa.的潜在治疗点的作用.
    • 探索PTGES3在调节AR功能中的作用机制.

    主要方法:

    • 活细胞定量内源性AR光报告器的开发.
    • 基因组规模的CRISPRi流细胞计分类屏幕用于识别AR调节器.
    • 在AR驱动的PCa模型中验证已识别的基因,包括PTGES3.
    • 在体外和体内研究以阐明PTGES3的作用机制.

    主要成果:

    • 识别和验证已知的AR调节器 (HOXB13,GATA2) 和新奇的成功者,如PTGES3.
    • 在PCa模型中,PTGES3抑制导致AR蛋白损失,细胞循环停止和细胞死亡.
    • PTGES3表达与对AR导向疗法的耐药性有关.
    • PTGES3直接与AR结合,调节其稳定性,并调节其核功能.

    结论:

    • PTGES3 是前列腺癌的新型和必不可少的治疗点.
    • 向PTGES3可以克服对现有的AR导向疗法的抵抗机制.
    • PTGES3在AR蛋白调节和PCa.中的瘤性活性中发挥着重要作用.